Why the study?
Does BAY 63-2521 decrease peripheral vascular resistance and demonstrate a favorable safety profile in healthy male volunteers?
Does BAY 63-2521 decrease peripheral vascular resistance and demonstrate a favorable safety profile in healthy male volunteers?
BAY 63-2521 demonstrates a favorable safety profile and reduces peripheral vascular resistance in healthy male volunteers, supporting its potential development for pulmonary hypertension.
Background BAY 63–2521 is an oral soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO). It targets the reduced form of sGC, and enhances the sensitivity of the enzyme to low levels of bioavailable NO. Preclinical data suggest that BAY 63–2521 has the potential to be effective in the treatment of pulmonary hypertension, with the advantage of having a different mode of action from currently available agents.
No takes yet. Share an insight, caveat, or question.
Frey et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: